DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Mometasone and Markers of Airway Inflammation

Information source: Creighton University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Asthma

Intervention: Placebo (Drug); Mometasone Furoate (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Creighton University

Official(s) and/or principal investigator(s):
Thomas B Casale, MD, Principal Investigator, Affiliation: Creighton University

Summary

A post-marketing study to look at the effects of Asmanex on markers of airway inflammation.

Clinical Details

Official title: The Effects of Mometasone on Markers of Airway Inflammation

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: Exhaled Nitric Oxide

Secondary outcome: Airway Reactivity

Detailed description: Patients with asthma and not treated with anti-inflammatory medications were studied. This was a parallel, randomized, placebo-controlled study to investigate the effects of Asmanex on markers of airway inflammation including exhaled nitric oxide, airway reactivity, FEV1 and nitrates/nitrites and pH in exhaled breath condensate.

Eligibility

Minimum age: 19 Years. Maximum age: 50 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Asthma

- non-smoker

- FEV1 of at least 60% predicted

Exclusion Criteria:

- Pregnancy or lactation

- Corticosteroid use in past 30 days

Locations and Contacts

Creighton University Medical Center, Omaha, Nebraska 68131, United States
Additional Information

Starting date: August 2005
Last updated: July 3, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017